All In Biotech

Drug Trial Radar · NCT01951417

Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris

Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Pump Cetaphil® DermaControl™ Moisturizer SPF 30, and Cetaphil® DermaControl™ Foaming Wash Regimen in Patients With Mild to Moderate Acne Vulgaris

Last checked: Nov 20, 2026Latest source record: Aug 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

81

Actual

Start

Oct 2013

Primary completion

Mar 2014

Study completion Mar 2014

Sponsor

Lead sponsor
Galderma R&DIndustry
Sponsor type
Industry
First posted
Sep 26, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Supportive care
Who can join
All sexes, from 9 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center study to be conducted in the United States. The study will examine the change in lesion count in subjects using Epiduo® Gel Pump (once daily) in conjunction with Cetaphil® DermaControl™ Foam Wash (twice daily) and Moisturizer SPF 30 (once daily). Subjects with a clinical diagnosis of mild or moderate acne who are eligible for treatment with Epiduo® in accordance with the currently approved product labeling and who meet other inclusion/exclusion criteria are to be enrolled in the study and receive the study products for 8 weeks. Efficacy and safety assessments include: complete lesion counts, cutaneous irritation assessment, end of study treatment questionnaire, photographic evaluation for oiliness, skin tone, and P Acnes, hydration assessment, barrier function assessment, treatment compliance, and adverse event assessment.

Conditions

  • Acne

Interventions

  • Adapalene/BPO GelDrug

    Adapalene/Benzoyl Peroxide (BPO) Gel Pump (once daily)

  • Moisturizer SPF 30Other

    Moisturizer SPF 30 (once daily)

  • Foam WashOther

    Foam Wash (twice daily)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Lesion CountTime frame: Baseline, 2, 4, and 8 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Study Protocol, Inc.

    Boynton Beach, Florida

  • Tennessee Clinical Research Center

    Nashville, Tennessee

  • Stephens & Associates

    Carrollton, Texas

  • J&S Studies, Inc.

    College Station, Texas

  • The Dermatology Clinical Research Center of San Antonio

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.